Alvotech Past Earnings Performance
Past criteria checks 0/6
Alvotech's earnings have been declining at an average annual rate of -37.6%, while the Biotechs industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 14.3% per year.
Key information
-37.6%
Earnings growth rate
102.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 14.3% |
| Return on equity | n/a |
| Net Margin | -432.1% |
| Next Earnings Update | 28 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Alvotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 114 | -494 | 67 | 210 |
| 31 Dec 23 | 93 | -552 | 74 | 192 |
| 30 Sep 23 | 64 | -596 | 120 | 179 |
| 30 Jun 23 | 65 | -416 | 110 | 172 |
| 31 Mar 23 | 100 | -713 | 101 | 182 |
| 31 Dec 22 | 85 | -514 | 76 | 181 |
| 30 Sep 22 | 96 | 61 | 51 | 171 |
| 30 Jun 22 | 78 | -12 | 34 | 187 |
| 31 Mar 22 | 39 | -42 | 66 | 190 |
| 31 Dec 21 | 40 | -102 | 68 | 191 |
| 31 Dec 20 | 69 | -170 | 59 | 146 |
| 31 Dec 19 | 83 | -210 | 49 | 96 |
Quality Earnings: Z45 is currently unprofitable.
Growing Profit Margin: Z45 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Z45 is unprofitable, and losses have increased over the past 5 years at a rate of 37.6% per year.
Accelerating Growth: Unable to compare Z45's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: Z45 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: Z45's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.